Seattle Flow Your front door to Seattle's startup scene.
Sign in
Stream Events Podcasts Videos Communities
Taylor Soper / GeekWire

OncoSenX extends oversubscribed SAFE, plans $30M Series A to fund Phase I for genetics-targeted cancer therapies

Seattle biotech OncoSenX extended an oversubscribed SAFE to raise more capital for its lipid nanoparticle gene-delivery cancer therapies and plans a $30 million Series A to fund a Phase I trial; the spinout has raised $4.1 million so far and has six employees.

OOncoSenX
  • Link
  • Report this item
Replying to

No comments yet.

Seattle Flow — Your front door to Seattle's startup scene.

Run by Marcelo Calbucci MC
Send us a link Terms of Service Privacy For AI assistants
© 2026 Seattle Flow. All rights reserved.

Who liked this

Edit history

Seattle Flow

Your front door to Seattle's startup scene.

Seattle's startup scene is scattered across a hundred feeds, newsletters, and calendars. Seattle Flow brings it together: the news, events, podcasts, and people, plus what the community is saying about them. Every link sends you to the source.

Writing about a Seattle founder, fund, or startup? We'll help it get seen. Found a great story we missed? Send it in.

We're in beta and building this with the community. Tell us what you want to see here.

Seattle's startup scene, every day. The news, events, podcasts, and people, plus what everyone's saying about them. We're in beta: send us a story or tell us what you want to see.